In Cephalon Case, FTC Hopes For High Court Ruling
Despite its recent failure to challenge "pay for delay" settlements between generic-drug makers and brand-name-drug makers in court, the U.S. Federal Trade Commission has indicated its intent to continue to fight...To view the full article, register now.
Already a subscriber? Click here to view full article